Hangzhou Institute of Medicine, Chinese Academy of Sciences (20240269295). C-MET TARGETED APTAMER DRUG CONJUGATE AND METHOD FOR TREATING TUMOR simplified abstract

C-MET TARGETED APTAMER DRUG CONJUGATE AND METHOD FOR TREATING TUMOR

Organization Name

Hangzhou Institute of Medicine, Chinese Academy of Sciences

Inventor(s)

Weihong Tan of Hangzhou City (CN)

Xiangsheng Liu of Hangzhou City (CN)

Wencan Wu of Hangzhou City (CN)

Jiaxuan He of Hangzhou City (CN)

Yuan Liu of Hangzhou City (CN)

Zhaoqi Pan of Hangzhou City (CN)

Ting Fu of Hangzhou City (CN)

Sitao Xie of Hangzhou City (CN)

C-MET TARGETED APTAMER DRUG CONJUGATE AND METHOD FOR TREATING TUMOR - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240269295 titled 'C-MET TARGETED APTAMER DRUG CONJUGATE AND METHOD FOR TREATING TUMOR

Simplified Explanation: The patent application discusses a c-met targeted aptamer drug conjugate that shows promising results in inhibiting tumors in various models.

Key Features and Innovation:

• Drug conjugate c-met-APDC achieves a cytotoxic IC50 of 100 nm in cells with high c-met expression.
• Effectively inhibits tumors in animal models with high c-met expression.
• Achieves a 100% tumor inhibition rate in a triple negative breast cancer PDX model.
• Shows complete regression of transplanted tumors.
• Inhibits choroidal melanoma subcutaneous tumors by up to 98.13% when administered subcutaneously and 100% when injected intravitreally.

Potential Applications: The technology can be applied in cancer treatment, specifically targeting tumors with high c-met expression.

Problems Solved: This technology addresses the need for more effective and targeted cancer treatments, especially for tumors with high c-met expression.

Benefits: The technology offers a highly effective and targeted approach to tumor inhibition, potentially leading to better outcomes for cancer patients.

Commercial Applications: The technology could have significant commercial applications in the pharmaceutical industry for developing targeted cancer therapies.

Prior Art: Readers can explore prior research on c-met targeted therapies and aptamer drug conjugates in the field of biotechnology.

Frequently Updated Research: Stay updated on the latest research on c-met targeted therapies and aptamer drug conjugates for cancer treatment.

Questions about c-met targeted aptamer drug conjugate: 1. What are the potential challenges in scaling up the production of c-met targeted aptamer drug conjugates for commercial use? 2. How does the efficacy of c-met targeted aptamer drug conjugates compare to traditional cancer treatments like chemotherapy?

By providing a detailed and informative overview of the patent application, readers can gain a better understanding of the innovative technology and its potential impact in the field of biotechnology.

Original Abstract Submitted

the present application relates to the field of biotechnology, and in particular to a c-met targeted aptamer drug conjugate. the drug conjugate c-met-apdc of the present application can achieve a cytotoxic icof 100 nm in a cell with high expression of c-met and a tumor model with high expression of c-met, effectively inhibit a tumor in an animal model, achieve a tumor inhibition rate of 100% for a triple negative breast cancer pdx model, and gain complete regression of a transplanted tumor. the inhibition rate of the drug conjugate administrated subcutaneously to choroidal melanoma as a subcutaneous tumor by tail vein is up to 98.13%, and the inhibition rate of the drug conjugate injected intravitreally into intraocular choroidal melanoma in situ is 100%, which realizes complete regression of the transplanted tumor.